{"schema_version":"secwatch.filing_event.v1","accession":"0001297184-23-000046","form_type":"8-K","ticker":"AMPH","cik":"0001297184","company_name":"Amphastar Pharmaceuticals, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.304663+00:00","generated_at":"2026-06-15T08:26:20.156703+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amphastar Q1 revenues $140M (+16% YoY); GAAP EPS $0.50, adj. EPS $0.62","bullets":["Net revenues $140.0M vs $120.4M YoY; GAAP net income $26.0M ($0.50 diluted EPS).","Adjusted non-GAAP net income $32.1M ($0.62 diluted EPS), up from $24.6M ($0.47) YoY.","Key growth drivers: glucagon, Primatene MIST, epinephrine; new launches include regadenoson and intranasal naloxone.","Proposed BAQSIMI acquisition noted as transformative for diabetes portfolio and branded product strategy."],"urls":{"canonical":"https://secwatch.observer/filing/0001297184-23-000046","json":"https://secwatch.observer/filing/0001297184-23-000046.json","markdown":"https://secwatch.observer/filing/0001297184-23-000046.md","text":"https://secwatch.observer/filing/0001297184-23-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1297184/000129718423000046/0001297184-23-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1297184/000129718423000046/amph-20230509x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T08:26:20.156703+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"74ab64d78cef26d571d5e26ca024009093a0920a","claim":"Amphastar Pharmaceuticals, Inc. reported three months ended March 31, 2023 results: revenue 140.0 million, net income 26.0 million, EPS 0.50.","evidence_excerpt":"Reports Net Revenues of $140.0 Million for the Three Months Ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1297184/000129718423000046/0001297184-23-000046-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2023"},{"label":"Revenue","value":"140.0 million"},{"label":"Net income","value":"26.0 million"},{"label":"EPS","value":"0.50"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}